Pharma & Healthcare
Generic and Biosimilar Pharmaceuticals - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Nov 05, 24
- ID: 656250
- Pages: 129
- Figures: 201
- Views: 5
The global market for Generic and Biosimilar Pharmaceuticals was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Generic and Biosimilar Pharmaceuticals by region & country, by Type, and by Application.
The Generic and Biosimilar Pharmaceuticals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Generic and Biosimilar Pharmaceuticals manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Generic and Biosimilar Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Generic and Biosimilar Pharmaceuticals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Generic and Biosimilar Pharmaceuticals by region & country, by Type, and by Application.
The Generic and Biosimilar Pharmaceuticals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Generic and Biosimilar Pharmaceuticals manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Generic and Biosimilar Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Generic and Biosimilar Pharmaceuticals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Generic and Biosimilar Pharmaceuticals Product Introduction
1.2 Global Generic and Biosimilar Pharmaceuticals Market Size Forecast
1.3 Generic and Biosimilar Pharmaceuticals Market Trends & Drivers
1.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
1.3.2 Generic and Biosimilar Pharmaceuticals Market Drivers & Opportunity
1.3.3 Generic and Biosimilar Pharmaceuticals Market Challenges
1.3.4 Generic and Biosimilar Pharmaceuticals Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Generic and Biosimilar Pharmaceuticals Players Revenue Ranking (2023)
2.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2019-2024)
2.3 Key Companies Generic and Biosimilar Pharmaceuticals Manufacturing Base Distribution and Headquarters
2.4 Key Companies Generic and Biosimilar Pharmaceuticals Product Offered
2.5 Key Companies Time to Begin Mass Production of Generic and Biosimilar Pharmaceuticals
2.6 Generic and Biosimilar Pharmaceuticals Market Competitive Analysis
2.6.1 Generic and Biosimilar Pharmaceuticals Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Interferon
3.1.3 Erythropoietin
3.1.4 Insulin
3.1.5 Vaccines
3.1.6 Other
3.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type
3.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (2019-2030)
3.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tumor
4.1.2 Diabetes
4.1.3 Cardiovascular
4.1.4 Hemophilia
4.1.5 Other
4.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application
4.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (2019-2030)
4.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region
5.1.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024)
5.1.3 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030)
5.1.4 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.2.2 North America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.3.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.4.2 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.5.2 South America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.6.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value
6.3 United States
6.3.1 United States Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.3.2 United States Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.4.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.5.2 China Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.5.3 China Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.6.2 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.7.2 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.8.2 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.9.2 India Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.9.3 India Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Profile
7.2.2 Amgen Main Business
7.2.3 Amgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Recent Developments
7.3 AbbVie
7.3.1 AbbVie Profile
7.3.2 AbbVie Main Business
7.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi-Aventis Recent Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Profile
7.4.2 Sanofi-Aventis Main Business
7.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi-Aventis Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Profile
7.5.2 Johnson & Johnson Main Business
7.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.5.5 Johnson & Johnson Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Profile
7.7.2 Novo Nordisk Main Business
7.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.7.5 Novo Nordisk Recent Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Profile
7.8.2 Eli Lilly Main Business
7.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly Recent Developments
7.9 Novartis
7.9.1 Novartis Profile
7.9.2 Novartis Main Business
7.9.3 Novartis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.9.5 Novartis Recent Developments
7.10 Merck
7.10.1 Merck Profile
7.10.2 Merck Main Business
7.10.3 Merck Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.10.5 Merck Recent Developments
7.11 3sbio
7.11.1 3sbio Profile
7.11.2 3sbio Main Business
7.11.3 3sbio Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.11.5 3sbio Recent Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Profile
7.12.2 Changchun High Tech Main Business
7.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.12.5 Changchun High Tech Recent Developments
7.13 CP Guojian
7.13.1 CP Guojian Profile
7.13.2 CP Guojian Main Business
7.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.13.5 CP Guojian Recent Developments
7.14 Biotech
7.14.1 Biotech Profile
7.14.2 Biotech Main Business
7.14.3 Biotech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.14.5 Biotech Recent Developments
7.15 Gelgen
7.15.1 Gelgen Profile
7.15.2 Gelgen Main Business
7.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.15.5 Gelgen Recent Developments
7.16 Innovent
7.16.1 Innovent Profile
7.16.2 Innovent Main Business
7.16.3 Innovent Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.16.5 Innovent Recent Developments
7.17 Dong Bao
7.17.1 Dong Bao Profile
7.17.2 Dong Bao Main Business
7.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.17.5 Dong Bao Recent Developments
7.18 Ganlee
7.18.1 Ganlee Profile
7.18.2 Ganlee Main Business
7.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.18.5 Ganlee Recent Developments
8 Industry Chain Analysis
8.1 Generic and Biosimilar Pharmaceuticals Industrial Chain
8.2 Generic and Biosimilar Pharmaceuticals Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Generic and Biosimilar Pharmaceuticals Sales Model
8.5.2 Sales Channel
8.5.3 Generic and Biosimilar Pharmaceuticals Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Generic and Biosimilar Pharmaceuticals Product Introduction
1.2 Global Generic and Biosimilar Pharmaceuticals Market Size Forecast
1.3 Generic and Biosimilar Pharmaceuticals Market Trends & Drivers
1.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
1.3.2 Generic and Biosimilar Pharmaceuticals Market Drivers & Opportunity
1.3.3 Generic and Biosimilar Pharmaceuticals Market Challenges
1.3.4 Generic and Biosimilar Pharmaceuticals Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Generic and Biosimilar Pharmaceuticals Players Revenue Ranking (2023)
2.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2019-2024)
2.3 Key Companies Generic and Biosimilar Pharmaceuticals Manufacturing Base Distribution and Headquarters
2.4 Key Companies Generic and Biosimilar Pharmaceuticals Product Offered
2.5 Key Companies Time to Begin Mass Production of Generic and Biosimilar Pharmaceuticals
2.6 Generic and Biosimilar Pharmaceuticals Market Competitive Analysis
2.6.1 Generic and Biosimilar Pharmaceuticals Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Interferon
3.1.3 Erythropoietin
3.1.4 Insulin
3.1.5 Vaccines
3.1.6 Other
3.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type
3.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (2019-2030)
3.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tumor
4.1.2 Diabetes
4.1.3 Cardiovascular
4.1.4 Hemophilia
4.1.5 Other
4.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application
4.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (2019-2030)
4.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region
5.1.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024)
5.1.3 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030)
5.1.4 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.2.2 North America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.3.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.4.2 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.5.2 South America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.6.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value
6.3 United States
6.3.1 United States Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.3.2 United States Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.4.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.5.2 China Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.5.3 China Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.6.2 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.7.2 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.8.2 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.9.2 India Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.9.3 India Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Profile
7.2.2 Amgen Main Business
7.2.3 Amgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Recent Developments
7.3 AbbVie
7.3.1 AbbVie Profile
7.3.2 AbbVie Main Business
7.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi-Aventis Recent Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Profile
7.4.2 Sanofi-Aventis Main Business
7.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi-Aventis Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Profile
7.5.2 Johnson & Johnson Main Business
7.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.5.5 Johnson & Johnson Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Profile
7.7.2 Novo Nordisk Main Business
7.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.7.5 Novo Nordisk Recent Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Profile
7.8.2 Eli Lilly Main Business
7.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly Recent Developments
7.9 Novartis
7.9.1 Novartis Profile
7.9.2 Novartis Main Business
7.9.3 Novartis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.9.5 Novartis Recent Developments
7.10 Merck
7.10.1 Merck Profile
7.10.2 Merck Main Business
7.10.3 Merck Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.10.5 Merck Recent Developments
7.11 3sbio
7.11.1 3sbio Profile
7.11.2 3sbio Main Business
7.11.3 3sbio Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.11.5 3sbio Recent Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Profile
7.12.2 Changchun High Tech Main Business
7.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.12.5 Changchun High Tech Recent Developments
7.13 CP Guojian
7.13.1 CP Guojian Profile
7.13.2 CP Guojian Main Business
7.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.13.5 CP Guojian Recent Developments
7.14 Biotech
7.14.1 Biotech Profile
7.14.2 Biotech Main Business
7.14.3 Biotech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.14.5 Biotech Recent Developments
7.15 Gelgen
7.15.1 Gelgen Profile
7.15.2 Gelgen Main Business
7.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.15.5 Gelgen Recent Developments
7.16 Innovent
7.16.1 Innovent Profile
7.16.2 Innovent Main Business
7.16.3 Innovent Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.16.5 Innovent Recent Developments
7.17 Dong Bao
7.17.1 Dong Bao Profile
7.17.2 Dong Bao Main Business
7.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.17.5 Dong Bao Recent Developments
7.18 Ganlee
7.18.1 Ganlee Profile
7.18.2 Ganlee Main Business
7.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.18.5 Ganlee Recent Developments
8 Industry Chain Analysis
8.1 Generic and Biosimilar Pharmaceuticals Industrial Chain
8.2 Generic and Biosimilar Pharmaceuticals Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Generic and Biosimilar Pharmaceuticals Sales Model
8.5.2 Sales Channel
8.5.3 Generic and Biosimilar Pharmaceuticals Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Generic and Biosimilar Pharmaceuticals Market Trends
Table 2. Generic and Biosimilar Pharmaceuticals Market Drivers & Opportunity
Table 3. Generic and Biosimilar Pharmaceuticals Market Challenges
Table 4. Generic and Biosimilar Pharmaceuticals Market Restraints
Table 5. Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Generic and Biosimilar Pharmaceuticals Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Generic and Biosimilar Pharmaceuticals Product Type
Table 9. Key Companies Time to Begin Mass Production of Generic and Biosimilar Pharmaceuticals
Table 10. Global Generic and Biosimilar Pharmaceuticals Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024) & (%)
Table 27. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value, (2025-2030) & (US$ Million)
Table 31. Roche Basic Information List
Table 32. Roche Description and Business Overview
Table 33. Roche Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 34. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Roche (2019-2024)
Table 35. Roche Recent Developments
Table 36. Amgen Basic Information List
Table 37. Amgen Description and Business Overview
Table 38. Amgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 39. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Amgen (2019-2024)
Table 40. Amgen Recent Developments
Table 41. AbbVie Basic Information List
Table 42. AbbVie Description and Business Overview
Table 43. AbbVie Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 44. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of AbbVie (2019-2024)
Table 45. AbbVie Recent Developments
Table 46. Sanofi-Aventis Basic Information List
Table 47. Sanofi-Aventis Description and Business Overview
Table 48. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 49. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Sanofi-Aventis (2019-2024)
Table 50. Sanofi-Aventis Recent Developments
Table 51. Johnson & Johnson Basic Information List
Table 52. Johnson & Johnson Description and Business Overview
Table 53. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 54. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Johnson & Johnson (2019-2024)
Table 55. Johnson & Johnson Recent Developments
Table 56. Pfizer Basic Information List
Table 57. Pfizer Description and Business Overview
Table 58. Pfizer Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 59. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Pfizer (2019-2024)
Table 60. Pfizer Recent Developments
Table 61. Novo Nordisk Basic Information List
Table 62. Novo Nordisk Description and Business Overview
Table 63. Novo Nordisk Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 64. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Novo Nordisk (2019-2024)
Table 65. Novo Nordisk Recent Developments
Table 66. Eli Lilly Basic Information List
Table 67. Eli Lilly Description and Business Overview
Table 68. Eli Lilly Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 69. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Eli Lilly (2019-2024)
Table 70. Eli Lilly Recent Developments
Table 71. Novartis Basic Information List
Table 72. Novartis Description and Business Overview
Table 73. Novartis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 74. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Novartis (2019-2024)
Table 75. Novartis Recent Developments
Table 76. Merck Basic Information List
Table 77. Merck Description and Business Overview
Table 78. Merck Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 79. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Merck (2019-2024)
Table 80. Merck Recent Developments
Table 81. 3sbio Basic Information List
Table 82. 3sbio Description and Business Overview
Table 83. 3sbio Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 84. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of 3sbio (2019-2024)
Table 85. 3sbio Recent Developments
Table 86. Changchun High Tech Basic Information List
Table 87. Changchun High Tech Description and Business Overview
Table 88. Changchun High Tech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 89. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Changchun High Tech (2019-2024)
Table 90. Changchun High Tech Recent Developments
Table 91. CP Guojian Basic Information List
Table 92. CP Guojian Description and Business Overview
Table 93. CP Guojian Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 94. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of CP Guojian (2019-2024)
Table 95. CP Guojian Recent Developments
Table 96. Biotech Basic Information List
Table 97. Biotech Description and Business Overview
Table 98. Biotech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 99. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Biotech (2019-2024)
Table 100. Biotech Recent Developments
Table 101. Gelgen Basic Information List
Table 102. Gelgen Description and Business Overview
Table 103. Gelgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 104. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Gelgen (2019-2024)
Table 105. Gelgen Recent Developments
Table 106. Innovent Basic Information List
Table 107. Innovent Description and Business Overview
Table 108. Innovent Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 109. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Innovent (2019-2024)
Table 110. Innovent Recent Developments
Table 111. Dong Bao Basic Information List
Table 112. Dong Bao Description and Business Overview
Table 113. Dong Bao Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 114. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Dong Bao (2019-2024)
Table 115. Dong Bao Recent Developments
Table 116. Ganlee Basic Information List
Table 117. Ganlee Description and Business Overview
Table 118. Ganlee Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 119. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Ganlee (2019-2024)
Table 120. Ganlee Recent Developments
Table 121. Key Raw Materials Lists
Table 122. Raw Materials Key Suppliers Lists
Table 123. Generic and Biosimilar Pharmaceuticals Downstream Customers
Table 124. Generic and Biosimilar Pharmaceuticals Distributors List
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Generic and Biosimilar Pharmaceuticals Product Picture
Figure 2. Global Generic and Biosimilar Pharmaceuticals Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 4. Generic and Biosimilar Pharmaceuticals Report Years Considered
Figure 5. Global Generic and Biosimilar Pharmaceuticals Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2023
Figure 7. Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Monoclonal Antibodies Picture
Figure 9. Interferon Picture
Figure 10. Erythropoietin Picture
Figure 11. Insulin Picture
Figure 12. Vaccines Picture
Figure 13. Other Picture
Figure 14. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Type, 2023 & 2030
Figure 16. Product Picture of Tumor
Figure 17. Product Picture of Diabetes
Figure 18. Product Picture of Cardiovascular
Figure 19. Product Picture of Hemophilia
Figure 20. Product Picture of Other
Figure 21. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Application, 2023 & 2030
Figure 23. North America Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 24. North America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 25. Europe Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 26. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 27. Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 28. Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 29. South America Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 30. South America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 31. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 32. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 33. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value (%), (2019-2030)
Figure 34. United States Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 35. United States Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 36. United States Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 37. Europe Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 38. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 39. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 40. China Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 41. China Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 42. China Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 43. Japan Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 44. Japan Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 45. Japan Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 46. South Korea Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 47. South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 48. South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 49. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 50. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 51. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 52. India Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 53. India Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 54. India Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 55. Generic and Biosimilar Pharmaceuticals Industrial Chain
Figure 56. Generic and Biosimilar Pharmaceuticals Manufacturing Cost Structure
Figure 57. Channels of Distribution (Direct Sales, and Distribution)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Table 1. Generic and Biosimilar Pharmaceuticals Market Trends
Table 2. Generic and Biosimilar Pharmaceuticals Market Drivers & Opportunity
Table 3. Generic and Biosimilar Pharmaceuticals Market Challenges
Table 4. Generic and Biosimilar Pharmaceuticals Market Restraints
Table 5. Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Generic and Biosimilar Pharmaceuticals Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Generic and Biosimilar Pharmaceuticals Product Type
Table 9. Key Companies Time to Begin Mass Production of Generic and Biosimilar Pharmaceuticals
Table 10. Global Generic and Biosimilar Pharmaceuticals Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Generic and Biosimilar Pharmaceuticals Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024) & (%)
Table 27. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value, (2025-2030) & (US$ Million)
Table 31. Roche Basic Information List
Table 32. Roche Description and Business Overview
Table 33. Roche Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 34. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Roche (2019-2024)
Table 35. Roche Recent Developments
Table 36. Amgen Basic Information List
Table 37. Amgen Description and Business Overview
Table 38. Amgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 39. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Amgen (2019-2024)
Table 40. Amgen Recent Developments
Table 41. AbbVie Basic Information List
Table 42. AbbVie Description and Business Overview
Table 43. AbbVie Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 44. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of AbbVie (2019-2024)
Table 45. AbbVie Recent Developments
Table 46. Sanofi-Aventis Basic Information List
Table 47. Sanofi-Aventis Description and Business Overview
Table 48. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 49. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Sanofi-Aventis (2019-2024)
Table 50. Sanofi-Aventis Recent Developments
Table 51. Johnson & Johnson Basic Information List
Table 52. Johnson & Johnson Description and Business Overview
Table 53. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 54. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Johnson & Johnson (2019-2024)
Table 55. Johnson & Johnson Recent Developments
Table 56. Pfizer Basic Information List
Table 57. Pfizer Description and Business Overview
Table 58. Pfizer Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 59. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Pfizer (2019-2024)
Table 60. Pfizer Recent Developments
Table 61. Novo Nordisk Basic Information List
Table 62. Novo Nordisk Description and Business Overview
Table 63. Novo Nordisk Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 64. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Novo Nordisk (2019-2024)
Table 65. Novo Nordisk Recent Developments
Table 66. Eli Lilly Basic Information List
Table 67. Eli Lilly Description and Business Overview
Table 68. Eli Lilly Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 69. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Eli Lilly (2019-2024)
Table 70. Eli Lilly Recent Developments
Table 71. Novartis Basic Information List
Table 72. Novartis Description and Business Overview
Table 73. Novartis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 74. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Novartis (2019-2024)
Table 75. Novartis Recent Developments
Table 76. Merck Basic Information List
Table 77. Merck Description and Business Overview
Table 78. Merck Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 79. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Merck (2019-2024)
Table 80. Merck Recent Developments
Table 81. 3sbio Basic Information List
Table 82. 3sbio Description and Business Overview
Table 83. 3sbio Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 84. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of 3sbio (2019-2024)
Table 85. 3sbio Recent Developments
Table 86. Changchun High Tech Basic Information List
Table 87. Changchun High Tech Description and Business Overview
Table 88. Changchun High Tech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 89. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Changchun High Tech (2019-2024)
Table 90. Changchun High Tech Recent Developments
Table 91. CP Guojian Basic Information List
Table 92. CP Guojian Description and Business Overview
Table 93. CP Guojian Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 94. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of CP Guojian (2019-2024)
Table 95. CP Guojian Recent Developments
Table 96. Biotech Basic Information List
Table 97. Biotech Description and Business Overview
Table 98. Biotech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 99. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Biotech (2019-2024)
Table 100. Biotech Recent Developments
Table 101. Gelgen Basic Information List
Table 102. Gelgen Description and Business Overview
Table 103. Gelgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 104. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Gelgen (2019-2024)
Table 105. Gelgen Recent Developments
Table 106. Innovent Basic Information List
Table 107. Innovent Description and Business Overview
Table 108. Innovent Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 109. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Innovent (2019-2024)
Table 110. Innovent Recent Developments
Table 111. Dong Bao Basic Information List
Table 112. Dong Bao Description and Business Overview
Table 113. Dong Bao Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 114. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Dong Bao (2019-2024)
Table 115. Dong Bao Recent Developments
Table 116. Ganlee Basic Information List
Table 117. Ganlee Description and Business Overview
Table 118. Ganlee Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
Table 119. Revenue (US$ Million) in Generic and Biosimilar Pharmaceuticals Business of Ganlee (2019-2024)
Table 120. Ganlee Recent Developments
Table 121. Key Raw Materials Lists
Table 122. Raw Materials Key Suppliers Lists
Table 123. Generic and Biosimilar Pharmaceuticals Downstream Customers
Table 124. Generic and Biosimilar Pharmaceuticals Distributors List
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Generic and Biosimilar Pharmaceuticals Product Picture
Figure 2. Global Generic and Biosimilar Pharmaceuticals Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 4. Generic and Biosimilar Pharmaceuticals Report Years Considered
Figure 5. Global Generic and Biosimilar Pharmaceuticals Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2023
Figure 7. Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Monoclonal Antibodies Picture
Figure 9. Interferon Picture
Figure 10. Erythropoietin Picture
Figure 11. Insulin Picture
Figure 12. Vaccines Picture
Figure 13. Other Picture
Figure 14. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Type, 2023 & 2030
Figure 16. Product Picture of Tumor
Figure 17. Product Picture of Diabetes
Figure 18. Product Picture of Cardiovascular
Figure 19. Product Picture of Hemophilia
Figure 20. Product Picture of Other
Figure 21. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Application, 2023 & 2030
Figure 23. North America Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 24. North America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 25. Europe Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 26. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 27. Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 28. Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 29. South America Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 30. South America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 31. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value (2019-2030) & (US$ Million)
Figure 32. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
Figure 33. Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value (%), (2019-2030)
Figure 34. United States Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 35. United States Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 36. United States Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 37. Europe Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 38. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 39. Europe Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 40. China Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 41. China Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 42. China Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 43. Japan Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 44. Japan Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 45. Japan Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 46. South Korea Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 47. South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 48. South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 49. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 50. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 51. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 52. India Generic and Biosimilar Pharmaceuticals Sales Value, (2019-2030) & (US$ Million)
Figure 53. India Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
Figure 54. India Generic and Biosimilar Pharmaceuticals Sales Value by Application (%), 2023 VS 2030
Figure 55. Generic and Biosimilar Pharmaceuticals Industrial Chain
Figure 56. Generic and Biosimilar Pharmaceuticals Manufacturing Cost Structure
Figure 57. Channels of Distribution (Direct Sales, and Distribution)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232